Reviewer’s report

Title: Tetrabenazine as Anti-Chorea Therapy in Huntington Disease: An Open-Label Continuation Study

Version: 1 Date: 23 April 2009

Reviewer: Raymund Roos

Reviewer’s report:

Tetrabenazine as anti-chorea therapy in Huntington disease: an open label continuation study.

The article describes the long term follow up of the use of tetrabenazine (TBZ) in Huntington disease patients (HD). It is an open study with the limitations known, as the authors indicate. A multi centre study.

The aim to look at the long term efficacy and side effects was followed in the study and article.

Despite the structure of the study (open uncontrolled) the information is useful for clinical practice.

Minor but essential issue is the uncertainty about the 26 patient lost for the study. They stopped! It is very informative to know the clinical characteristics of those who stopped and the reason, more precisely given, why they stopped. (Loss of efficacy?; otherwise?; center bound?)

A second point is that the numbers of those who were analyzed at the end are a little confusing: 42 or 45 patients (methods, results and figure). A point that seems easy to resolve.

A really minor point is the lay-out and the lack of details in table (fi years at the point of the participants).

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

'I declare that I have no competing interests'